Aerie's eye drug meets main goal in late-stage study, shares jump

September 15, 2016 1:09 PM

2 0

Aerie's eye drug meets main goal in late-stage study, shares jump

Aerie Pharmaceuticals said on Wednesday its eyedrug met the main goal in a late stage study, sending its shares up 71 percent in extended trading.

The company's drug, Roclatan, is a fixed-dose combination of its lead drug Rhopressa and latanoprost, one of the most widely prescribed glaucoma drugs.

Read more

To category page

Loading...